News Releases

Treatment with BDC-1001 at the recommended Phase 2 dose (RP2D) resulted in 29% objective response rate in evaluable patients with HER2-positive tumors, in both monotherapy and in combination with nivolumab 20 mg/kg dosed every other week (q2w) was selected as the RP2D BDC-1001 advancing to a

Comprehensive BDC-1001 clinical safety and efficacy data as a single agent and in combination with nivolumab, including RP2D, to be presented at ASCO 2023 BDC-1001 Phase 2 program expected to initiate in 2023 in HER2+ colorectal, endometrial, gastroesophageal, and breast cancer Cash balance of

Comprehensive Phase 1 data at ASCO support initiation of two Phase 2 trials REDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer, today

Positive topline data from BDC-1001 dose-escalation clinical study validates the ability of the Boltbody™ ISAC platform to generate anti-tumor activity with acceptable safety BDC-1001 advances into a focused Phase 2 program commencing in 2023: a trial as monotherapy and in combination with

BDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with nivolumab Data support selection of a recommended Phase 2 dose and advancement into Phase 2 studies in breast,

REDWOOD CITY, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that it will present a poster with new preclinical data for BDC-3042, a

REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will present a company overview at the Cowen 43rd Annual

REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in two upcoming conferences in